Natera (NASDAQ:NTRA) Insider Sells $120,803.02 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 302 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total transaction of $120,803.02. Following the transaction, the insider owned 195,276 shares in the company, valued at approximately $78,112,352.76. The trade was a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $382,853.32.
• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total value of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01.

Natera Stock Down 14.6%

NASDAQ NTRA opened at $310.67 on Friday. The firm’s fifty day simple moving average is $380.25 and its two-hundred day simple moving average is $269.68. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. During the same period in the prior year, the business earned ($0.64) earnings per share. The firm’s quarterly revenue was up 34.1% compared to the same quarter last year. On average, analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Diversified Trust Co lifted its holdings in shares of Natera by 81.4% in the third quarter. Diversified Trust Co now owns 2,353 shares of the medical research company’s stock worth $973,000 after acquiring an additional 1,056 shares during the last quarter. Aberdeen Group plc increased its stake in Natera by 26,462.7% during the 3rd quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock valued at $578,136,000 after purchasing an additional 1,393,528 shares in the last quarter. HBE Wealth Management LLC acquired a new position in Natera in the 3rd quarter valued at about $208,000. Allworth Financial LP increased its stake in Natera by 2.5% in the 3rd quarter. Allworth Financial LP now owns 3,975 shares of the medical research company’s stock valued at $1,643,000 after buying an additional 97 shares during the period. Finally, Private Advisory Group LLC acquired a new position in shares of Natera in the 3rd quarter valued at about $3,521,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on NTRA. Stephens boosted their price target on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Rothschild & Co Redburn started coverage on Natera in a report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 target price for the company. Roth Capital assumed coverage on Natera in a report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price on the stock. UBS Group upped their price target on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, BTIG Research upped their price objective on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $391.69.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.